Ontology highlight
ABSTRACT:
SUBMITTER: Cordes LM
PROVIDER: S-EPMC10400131 | biostudies-literature | 2023 Aug
REPOSITORIES: biostudies-literature
Cordes Lisa M LM Karzai Fatima F Figg William D WD Madan Ravi A RA
The oncologist 20230801 8
Androgen deprivation therapy (ADT) has been a mainstay of prostate cancer treatment for decades. Relugolix was FDA-approved in 2020 and is currently the only ADT option via an oral route. While the opportunity to use an oral medication for this indication has some advantages, a balanced discussion is required to understand in what clinical settings this agent truly has benefit over long-acting injectable formulations of ADT. Furthermore, patient preference, compliance, financial toxicity, and pe ...[more]